Marc Lopez, Emerence Crompot, Emmanuelle Josselin, Anne Farina, Marion Rubis, Remy Castellano, Joanna Fares, Maria Wehbe, Yves Collette, Emmanuelle Charafe, Stéphanie Blanchin, François Romagne, Anikó Pálfi, Torsten Hechler, Andreas Pahl, Hatem A Azim, Florence Lhospice, Emilie Mamessier, François Bertucci, Jack Elands, Xavier Préville, Daniel Olive
{"title":"ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing Tumors.","authors":"Marc Lopez, Emerence Crompot, Emmanuelle Josselin, Anne Farina, Marion Rubis, Remy Castellano, Joanna Fares, Maria Wehbe, Yves Collette, Emmanuelle Charafe, Stéphanie Blanchin, François Romagne, Anikó Pálfi, Torsten Hechler, Andreas Pahl, Hatem A Azim, Florence Lhospice, Emilie Mamessier, François Bertucci, Jack Elands, Xavier Préville, Daniel Olive","doi":"10.1158/2767-9764.CRC-24-0176","DOIUrl":null,"url":null,"abstract":"<p><strong>Significance: </strong>ETx-22, a novel ADC combining a tumor nectin-4-specific antibody and an innovative linker to exatecan, demonstrates significant and durable responses in low-target-expressing tumor models that are resistant to MMAE-based EV and has a better toxicity profile. This new ADC has the potential to benefit additional patient populations beyond its current indication.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"2998-3012"},"PeriodicalIF":2.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11583010/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2767-9764.CRC-24-0176","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Significance: ETx-22, a novel ADC combining a tumor nectin-4-specific antibody and an innovative linker to exatecan, demonstrates significant and durable responses in low-target-expressing tumor models that are resistant to MMAE-based EV and has a better toxicity profile. This new ADC has the potential to benefit additional patient populations beyond its current indication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
